Announcement PDF Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com ASX ANNOUNCEMENT 27 May 2026 Expected Timing of Clinical Trial Results Melbourne, Australia; 27 May 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, provides an update on the expectedtimingof results fromtwo majorefficacytrialswithitsCymerus™iPSC1 -derived MSC2 products. Phase 3 Osteoarthritis Trial (CYP-004) The Australian Phase 3 SCUlpTOR3 trial of CYP-004 in patients with osteoarthritis of the knee is being conductedby theUniversityof Sydney(USYD)andfunded through an NHMRC4 projectgrant.CYP-004is Cynata’s Cymerus™ iPSC-derived MSC product candidate for intra-articular injection (injection into a joint),designed to calmjointinflammation,relievepainandprotectcartilage.Thetrialenrolledatotalof 321 patients, who were randomised to receive either CYP-004 or placebo, with co-primary endpoints assessing change in pain and cartilage thickness. USYDhas informedtheCompany thatthe study database has beensuccessfullylocked, the process of data analysis is now progressing well, and results are expected during June 2026. Phase 2 acute Graft versus Host Disease Trial (CYP-001) The multi-national Phase 2 trial of CYP-001 in adults with acute graft versus host disease (aGvHD) is being conducted by Cynata. CYP-001 is Cynata’sCymerus™ iPSC-derivedMSCproductfor intravenous use, designed tomodulatetheimmunesystemandimproveboth responserates andsurvivaloutcomes in aGvHD. A total of 65 participants were enrolled across clinical centres in Australia, the USA and Europe, randomised to receive either steroids plus CYP-001 or steroids plus placebo. The primary endpoint is Overall Response Rate at Day 28. Database lock for this trial is expected to occur in early June 2026, with results anticipated in late June or early July. Dr Kilian Kelly, Cynata’s Chief Executive Officer and Managing Director, said: "A great deal of progress has been made with the process of data monitoring, cleaning, quality control andanalysisforthesetwohugelyimportant trials.Eachofthesereadoutsinitsownright hasthepotential to betransformativefortheCompany, and toset us on course toimprovethelivesof manypatientswith these serious diseases. We look forward to sharing the results with our investors as soon as possible." -ENDS- Authorised for release by Dr Kilian Kelly, CEO & Managing Director CONTACTS: Dr Kilian Kelly, CEO & MD,Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak,Media Contact,+61 (0)400 434 299, investors@cynata.com About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes thechallenges and limitations of conventional MSCproduction byusing induced pluripotent stemcells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistencyresulting fromconventional methods. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing:a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com CYP-001 in patients undergoing kidneytransplantation;and aPhase3 trial of CYP-004 in osteoarthritis.In addition,Cynatahas demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokinerelease syndrome. 1 iPSC = induced pluripotent stemcell. 2 MSC= mesenchymal stem (or stromal) cell. 3 SCUlpTOR = StemCells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis 4 NHMRC-= National Health and Medical Research Council